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• APS should be considered in all patients with digital ischaemic symptoms 
• APS may be an important driver of SSc-related digital ulceration/necrosis 
• Identification of SSc-associated APS opens up new therapeutic options for acute 
management and secondary prevention  





Antiphospholipid syndrome (APS) is an acquired, autoimmune thrombophilia that can occur as 
a primary disorder (with no associated disease) or secondary to infection, medication usage and 
autoimmune rheumatic diseases (ARDs). The association between APS and systemic lupus 
erythematosus (SLE) is well established and practicing rheumatologists check for APS antibodies 
in the routine assessment of SLE, particularly if clinical features such as thrombotic events or 
pregnancy loss are present. APS secondary to systemic sclerosis (SSc)-related disorders is less 
widely recognised and easily overlooked. We describe 5 cases that highlight the varied breadth 
of clinical manifestations of APS in the context of SSc and related disorders. These cases range 
from uncomplicated Raynaud’s phenomenon, digital ulceration/necrosis, critical digital 
ischaemia/gangrene and rare internal organ complications of APS in SSc-spectrum disorders. To 
our knowledge, our cases include the first reported case of secondary APS contributing to 
digital necrosis in the context of RACAND syndrome (Raynaud’s phenomenon, Anti-Centromere 
Antibodies, and Necrosis of the Digits) and the first reported case of secondary APS in SSc 
causing posterior reversible encephalopathy syndrome (PRES). The case series is accompanied 
by a comprehensive review of the literature relevant to each case. Rheumatologists should be 
alert to the possibility of APS in SSc-spectrum disorders and should routinely check APS 
antibodies in all patients at diagnosis, and again later in the disease course if new features 









Antiphospholipid syndrome (APS) is an acquired, autoimmune thrombophilia in the presence of 
persistent antiphospholipid antibodies (aPLs)(1, 2). APS typically manifests as major arterial 
and/or venous thrombosis and/or obstetric morbidity; and it is these features that form the 
major classification criteria for APS(3). APS has several other recognised clinical manifestations, 
such as livedo reticularis, cutaneous necrosis, thrombocytopaenia, haemolytic anaemia, 
neuropsychiatric phenomena (e.g., transient ischaemic attacks (TIAs), cognitive deficits or white 
matter lesions), cardiac valve disease and nephropathy(2). APS can be classified as primary, 
whereby no underlying cause is identified, or secondary, in which there is an associated 
comorbidity, most commonly a systemic autoimmune rheumatic disease (ARD) or malignancy, 
or secondary to certain medications. The presence of aPLs in the context of systemic lupus 
erythematosus (SLE) was first noted in the early 1950s. Indeed, the APS itself was initially 
described in patients with ARD; the majority of whom had SLE(4, 5) . An APS screen forms an 
important part of the early diagnostic work-up of patients presenting with SLE or lupus patients 
developing atypical features later in the disease course(6).  
 
Systemic sclerosis (SSc) is a rare ARD characterized by obliterative microangiopathy, 
autoimmunity/inflammation and aberrant tissue remodelling(7). Digital vasculopathy is an 
important clinical feature of SSc, manifesting as symptoms of Raynaud’s phenomenon (RP) in 
virtually all patients and digital ulcers (DU) occurring in over half of patients at some stage 
during the disease course(8, 9). Digital vascular manifestations are generally assumed to be 
secondary to excessive vasospasm in response to cold exposure and the persistent ischaemic 




effects of an evolving obliterative microangiopathy(10, 11). Whilst less common than in SLE, 
aPLs have been reported in SSc; although estimates of the prevalence have varied greatly 
depending on the methodological approach taken(12-19). Patients with SSc-spectrum disorders 
and APS antibodies have been shown to be at greater risk of digital vascular disease, pulmonary 
arterial hypertension (PAH), pitting scars, macrovascular disease and nailfold capillary 
abnormalities(13, 20). Digital vascular complications are typically overlooked in descriptions of 
clinical features of APS and are not included in APS classification criteria(3). We report five 
cases of APS occurring in SSc-spectrum disorders. Our cases have been chosen to highlight the 
heterogeneity in clinical presentation and severity, emphasising the need for consideration of 
primary or secondary APS in patients with digital vasculopathy and those with established SSc-





A 47-year-old, non-smoking, Caucasian female presented with a 3-year history of short-lived 
self-limiting episodes (~5 minutes) of painful acrocyanosis of the fingers. The attacks were not 
provoked by cold exposure. There was no history of thrombosis and/or pregnancy loss. She had 
strong radial pulses bilaterally, with equal arm blood pressures, and no identifiable stigmata of 
connective tissue disease.  Nailfold capillaroscopy demonstrated normal capillary morphology 
and preserved capillary density (Figure 1A and B). Thermography of the hands revealed normal 
basal perfusion but delayed reperfusion of the left index finger at 5-minutes following a 1-




minute 20C local cold challenge test (Figure 1C and D). Moderately high titre for anti-
cardiolipin (aCL) IgM antibodies were identified on 2 occasions >12 weeks apart (72.5 MPL/mL 
and 51.1 MPL/mL, respectively). Anti-beta-2 glycoprotein 1 (anti-β2-GP1) IgM and IgG and lupus 
anticoagulant (LAC) were negative. There was a weak-positive anti-nuclear antibody (ANA) but 
extractable nuclear antigens (ENA) and double-stranded DNA antibodies were negative. Serum 
cryoglobulins and paraproteins were all negative/normal. Her HbA1c, lipid profile and plain 
films of the hands were normal. Anti-platelet therapy was commenced for suspected primary 
APS resulting in reversible digital occlusive microangiopathy and led to rapid and complete 
cessation of digital vascular symptoms, with benefits persisting at 6-months.   
 
Patient 2 
A 49-year-old, Caucasian male smoker (30 pack-year history) with an 11-year history of anti-
PM-Scl antibody positive limited cutaneous systemic sclerosis (lcSSc), presented with a 2-week 
history of progressive necrotic ulceration and acute ischaemia of the left 5th finger (Figure 2A). 
Co-morbidities included type 1 diabetes and a history of previous transient ischaemic attacks. 
Blood pressure and pulses were equal in both arms. Hand X-ray showed widespread calcinosis 
cutis within the digits (Figure 2B). Persistent positive aCL IgM antibodies (titres 91.6 MPL/ml 
and 98.9 MPL/mL respectively) were identified >12 weeks apart, leading to a diagnosis of 
secondary APS. LAC and anti-β2-GP1 were negative. Treatment with warfarin, intravenous 
iloprost (11 days), phosphodiesterase type 5 inhibitor and optimisation of traditional 
cardiovascular risk factors stabilised the clinical picture with no further progression of digital 
necrosis and evidence of subsequent healing (see Figure 2C).   






A 57- year-old, Caucasian female, with a 3-year history of anti-centromere positive lcSSc 
developed critical digital ischaemia and necrosis across multiple digits (Figure 3A). A history of 2 
prior miscarriages was noted but she had no history of previous thromboembolism. 
Examination revealed puffy fingers, but no overt sclerodactyly, and necrosis of the 3rd-5th digital 
pulps bilaterally (see Figure 3A). Pulses and blood pressures were equal in both arms. LAC was 
positive on 2 occasions but aCL antibodies were negative. She was diagnosed with the rare 
subtype of SSc-spectrum disease–RACAND syndrome (Raynaud’s phenomenon, Anti-
Centromere Antibodies, and Necrosis of the Digits) with secondary APS.  Treatment with 
warfarin and aggressive vasodilator therapy prevented progression of digital gangrene which 
was subsequently managed with surgical debridement of necrotic tissue (Figure 3B). There have 
been no further DU or digital necrosis over 4.5 years of follow-up. 
 
Patient 4 
A 54-year-old, non-smoking, Caucasian male had characteristic features of anti-centromere 
positive lcSSc with sclerodactyly, digital pitting, prior DU and typical abnormalities on nailfold 
capillaroscopy (Figure 3A and 3B). He had presented with worsening RP and acute right index 
and left middle finger subungal ulceration with necrosis, complicated by acro-osteolysis (Figure 
3C). He had a history of previous large right parietal infarct (Figure 3D) and myocardial 
infarction. These events had been attributed to traditional cardiovascular risk factors including 
hypertension, hypercholesterolaemia, type 2 diabetes (managed with metformin) and atrial 




fibrillation (anticoagulated with apixaban).  He was admitted for intravenous iloprost for his 
digital ischaemia and found to be strongly positive for aCL IgG (64.6 GPL/mL and 99.1 GPL/mL 
on 2 occasions 12 weeks apart), in addition to a weakly positive anti-β2-GP1 IgG (15 MPL/mL), 
consistent with secondary APS. His anticoagulation was switched to warfarin with resolution of 
his digital ischaemic complications and no further episodes after 8 months follow-up. 
 
Patient 5 
A 61-year-old, Caucasian female, with long-standing lcSSc (anti-Scl-70 antibody) complicated by 
RP, recurrent DU, interstitial lung disease (ILD) (Figure 4A) and small bowel bacterial 
overgrowth, developed acute worsening of dyspnoea despite relatively stable ILD on cross-
sectional imaging. Ventilation/perfusion imaging revealed a ventilation/perfusion mismatch 
consistent with acute pulmonary embolism, resulting in anticoagulation therapy with short-
term warfarin therapy for 6-months. She subsequently presented with severe, sudden-onset 
headache and confusion. An MRI showed changes consistent with posterior reversible 
encephalopathy syndrome (PRES). A high titre aCL IgM antibody was identified on 2 occasions 
>12 weeks apart (104 MPL/mL and 102.6 MPL/mL). In view of her history of previous 
thromboembolic disease and episode of PRES, the patient was diagnosed with APS secondary 
to SSc and commenced on long-term anticoagulation with warfarin. Her PRES resolved and 
there were no further thrombotic events following initiation of warfarin. 
 
Discussion 




The cases described highlight the need to consider APS as a potential cause of digital ischaemia 
and other rarer organ-specific complications of APS occurring in the context of Raynaud’s 
phenomenon and SSc-spectrum disorders.  
 
In 4 of the reported cases, digital vasculopathy was a prominent feature. Digital ischaemia is an 
uncommon extra-criteria clinical manifestation of APS and not included in the core Sydney 
classification criteria (also known as the revised Sapporo APS classification criteria) for APS(3). 
Given the high prevalence of RP and prominence of digital ischaemic symptoms in SSc, APS 
could easily be overlooked as a cause of digital vascular compromise. Moreover, SSc is not 
typically considered as a cause of APS. The Euro-phospholipid project assessed the clinical 
manifestations of APS in 1000 patients from 13 countries, of which 53.1% had primary APS, 
while SLE was the most common secondary cause at 36.2%(21).  In this cohort, SSc accounted 
for only 0.7% of cases(21). The most common presenting manifestation was DVT at 
approximately 32% of the cohort, trailed by thrombocytopenia at 22%, livedo reticularis at 20%, 
and stroke at 13%. Digital gangrene was noted to have occurred in 1.9%, at baseline with only a 
small number (n=14) of incident cases recorded during 5-years follow-up(21, 22). Digital 
gangrene and cutaneous necrosis, when present in APS, is generally a poor prognostic feature 
and often occurs in the context of Catastrophic APS (~70% of cases)(23). Digital necrosis was 
identified as an independent risk factor for mortality in APS in another retrospective survival 
analysis of 248 cases(24). A retrospective study of 45 patients presenting with digital necrosis 
over a 5-year period that excluded those with systemic sclerosis, identified primary APS as the 




cause in 7% of cases(25). Other analyses of unexplained digital ischaemia have reported APS as 
the aetiology of digital ischaemia in a similar proportion (3-8%)(26, 27). 
 
The European League Against Rheumatism have recently updated consensus guidelines on the 
management of APS(28). Consistent with the management instituted in case 1, primary 
thromboprophylaxis with low dose aspirin is recommended for symptomatic aPLs carriers (with 
or without other risk factors).  Secondary thromboprophylaxis with lifelong vitamin K antagonist 
is initiated for APS if a thrombotic event has occurred with higher intensity therapy for arterial 
thromboembolism. In cases 2-4, warfarin was commenced in view of APS-related thrombosis as 
the likely driver of digital necrosis. Direct oral anticoagulants are generally avoided following 
recent reports indicating they are less effective in preventing thrombosis in APS(29, 30).  
 
Case 1 relays that of an unusual mimic of Raynaud’s like symptoms, with investigations 
attributing symptoms to a reversible microangiopathy due to primary APS.  Excluding digital 
gangrene, the diverse spectrum of presentations of digital vasculopathy related to primary APS 
is largely limited to case reports and series. Table 1 presents an overview of previously 
published cases according to key digital complications.  
 
Established systemic sclerosis and secondary APS overlap was observed in 4 of our cases. We 
identified the full gamut of aPLs including aCL IgM, aCL IgG, anti-B2 GP1 IgG, and LAC, 
highlighting the need for an extended testing to exclude APS in SSc. Three of our cases had a 
history of earlier venous (Case 5) or arterial (Cases 2 and 5) events that had been assumed to be 




isolated events or related to conventional cardiovascular risk factors. Meta-analyses evaluating 
the frequency of aPLs  in the context of SSc have reported a prevalence of ~13-14%, with 
considerable heterogeneity in study design(15, 31). Consistent with our cases, a range of aPLs 
antibodies have been reported in SSc with a 1-2% prevalence of LAC, 9% prevalence of ACL 
(with IgM and IgG isotype prevalence of 7.8 percent and 12.8 percent, respectively), and a 9% 
frequency of anti-B2-GP1(15, 31). Meta-analyses identified an association between aPL 
positivity in SSc and the occurrence of venous thrombosis and miscarriage, but had conflicting 
conclusions on the overall influence of APS antibodies on the prevalence of digital ischaemic 
complications(15, 31). Repeat testing of aPLs after 12 weeks only occurred in three studies 
included in these meta-analyses, and the average aPLs titres did not meet APS diagnostic 
criteria. A subsequent multi-centre study estimated a lower APS prevalence in SSc of ~4%(14). 
In this study secondary APS was associated with higher RP severity and/or the presence of 
active DU(14). Antibodies targeting β2-GPI were an independent factor associated with active 
DU both in univariate and multivariate analysis(14). All of our cases demonstrated enduring 
presence of medium-high titre aPLs after 12 weeks. It is possible that positivity to aPL at lower 
titres may contribute to microvascular occlusions through shared thrombogenic pathways with 
SSc. 
 
As intravascular factors, platelet activation and thrombosis have long been suspected as 
contributing factors in SSc-related digital vasculopathy(32), it follows that the newly observed 
digital ischaemic features in SSc were presumably related to excessive vasospasm and the 
progressive obliterative microangiopathy of SSc. Treatment of SSc-associated RP and DU has 




generally focused on vasodilators(33), with only a limited number of clinical trials focusing on 
anti-platelet or anticoagulant therapy for SSc-related vasculopathy(32, 34). Vascular thrombosis 
in APS is the result of a ‘double-hit’ scenario in which the underlying milieu of antibodies 
targeting phospholipid binding proteins is necessary, but insufficient in isolation for thrombosis. 
Proinflammatory and prothrombotic signalling driven by additional external factors (e.g. 
infection, drugs, trauma) result in endothelial injury and suppression of in vivo anticoagulant 
pathways, provoking thrombus formation(35, 36). Digital ischaemia in SSc in association with 
aPLs antibodies may therefore be precipitated by pro-inflammatory signalling that necessitates 
intervention with immunomodulatory and anticoagulant therapy to manage acute ischaemic 
lesions and prevent recurrence. In our cases, the introduction of long-term anticoagulation 
prevented further digital complications, supporting the likelihood of APS as the prominent 
factor driving microcirculatory thrombosis and subsequent digital complications.  
 
The fourth case fulfils classification for both SSc and RACAND syndrome; which, to our 
knowledge, has not previously been reported in the context of aPLs. RACAND syndrome was 
originally coined following a series of four unusual cases mostly in elderly females, 
documenting the development of severe digital ischaemic lesions in the presence of ACAs, 
without dermal or visceral organ sclerosis(37). No identifiable histopathological changes were 
observed in arteries of amputated digits to account for the lesions(37). Whether this 
constellation of findings should be considered a distinct entity, or as part of the 
aetiopathogenic spectrum of SSc is debatable, although the apparent absence of overt 




sclerodactyly despite ACA positivity may indicate the need to consider RACAND syndrome a 
distinct clinical entity(37-39). 
 
Our final case of SSc with secondary APS resulted in the rare PRES (also known as reversible 
posterior leukoencephalopathy syndrome (RPLS)). There have only been a small number of 
reported cases of PRES in association with primary and secondary APS, often in association with 
high titre ACL IgM, as was found in our case(40-43). To our knowledge this is the first reported 
case of PRES occurring in the context of SSc and secondary APS. APS has previously been 
attributed as a risk factor for PRES in the context of normotension or mildly elevated blood 
pressure. It has been suggested that the pro-thrombotic state in APS engenders transient 
ischaemia, or causes increased vascular permeability of activation of vasoactive substances, 
common mechanisms linked to the general pathogenesis of PRES(42, 44).  
 
Conclusions 
In summary, our cases highlight the importance of considering APS in all patients presenting 
with digital ischaemic symptoms (particularly in the context of active ulceration or necrosis) or 
SSc patients with atypical features (particularly if there have been previous thrombotic events). 
APS antibodies should be routinely assessed at the time of SSc diagnosis and/or at the 
emergence of new features such as thromboembolic disease, new-onset digital ischaemic 
lesions and/or other potential extra-criteria features of APS such as PRES. The identification of 
secondary APS in SSc introduces the opportunity for additional therapeutic pathways beyond 
vasodilation for digital ischaemic lesions. SSc-associated APS should be managed according to 




evidence-based recommendations to prevent future digital ischaemic events or new 
thrombotic events in other organ systems.  
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Tables & Figures 
 
Figure 1. Digital microvascular imaging studies in patient with primary APS and Raynaud’s 
symptoms.  
A, Low magnification (x50) image of nailfold revealing normal appearances with no peri-ungal 
erythema; B, High magnification (x200) image of nailfold demonstrating normal capillary 
morphology and preserved capillary density; C, Baseline thermal image of the hands revealing 
well perfused digits with preserved positive thermal gradient; D, Delayed re-perfusion of the 
left index finger following local cold challenge (20°C for 1 minute) 
 
  




Figure 2. Progressive digital ischaemia and necrosis in a 49-year-old, male, smoker with lcSSc. 
Digital necrosis extending across the dorsal aspect  A(i) and pulp A(ii) of left 5th digit; B, 
Extensive calcinosis cutis (white arrows) on plain film of digits; C(i) and (ii), Arrested 
development of necrosis following introduction of warfarin and standard SSc-related digital 








Figure 3. Digital necrosis in a patient with RACAND syndrome and positive LAC.  
A, Digital ischaemic necrosis affecting 3rd to 5th digits; B, Digits following treatment with 
warfarin, intravenous iloprost and surgical debridement  
  




Figure 4. Cerebrovascular and digital vascular complications of secondary APS in a 54-year-old 
male with lcSSc. A, Image of the hands at presentation with sclerodactyly and subungal digital 
pitting; B, abnormal nailfolds with giant capillaries (black dashed arrows) and reduced capillary 
density; C, Acro-osteolysis of the 2nd and 4th distal phalanxes of the right hand (white arrows) 
after episodes of acute distal digital necrosis; D, Occipital cerebrovascular event causing 
homonymous quadrantanopia after warfarin replaced with DOAC. 
 
  




Figure 5. PRES in the setting of secondary APS in a 61-year-old female with lcSSc. A, 
Background non-specific interstitial pneumonia (NSIP) pattern demonstrated on CT chest; B, 
Posterior reversible encephalopathy syndrome (PRES) on CT head (white arrow). 
 
  




Table 1. Description of cases and management of the extra-criteria digital ischaemic manifestations related to primary APS.  
Case Details APS antibody Management and Outcome 
With Raynaud’s (or Raynaud’s-like) Phenomenon 
31F with RP and previous CVA and 3 miscarriages (mixed 
lengths of gestation) (45) 
aCL IgG (high titre-130 HU),  
Other antibodies not measuredⱡ 
NR 
27F with RP and previous transient visual loss and 4 
miscarriages (mixed lengths of gestation (45) 
aCL IgG (high titre-200 HU) and 
IgM (moderate titre) 
Others not measuredⱡ 
NR 
9F with 2-weeek history of pain and cyanosis of left toes, 
in the setting of previous Raynaud’s like symptoms (46) 
aCL IgG (high titre-125 GPL)* Vasodilators, including IV iloprost with resolution and 
no recurrence at 20-months of follow-up 
With Digital Ulcers (DU) 
60M with bilateral intermittent claudication and non-
healing ulcer of right toe, and 2-year history of RP (48) 
LAC Short-term anticoagulation and long-term dual-
antiplatelet therapy. Endovascular therapy for aortic 
involvement. Resolution and no recurrence at 12-
months of follow-up 
With other digital ischaemic symptoms 
8-month F with toe discolouration (49) 
 
aCL IgG (high titre-100 GPL)^ ⱡ Anticoagulation (short-term) and antiplatelet (long-
term) with resolution of symptoms, follow-up NR 
4F with painful discolouration of digits (49) aCL IgG (moderate titre-33 GPL)^ 
ⱡ 
Immunosuppression & antiplatelet therapy. Symptoms 
resolved after 1 week of therapy, aCL normalised after 6 
weeks, further follow-up NR 
38F with episodes of pain in the right index finger (50) 
 
aCL antibodies*ⱡ Anticoagulation and antiplatelet therapy. Resolution of 
digital symptoms, follow-up NR 
41F with acute digital ischaemia of left foot and previous 
DVTs and PE (51) 
aCL IgG (high titre-61 GPL)^ 
LAC^ 
 
Anticoagulation (INR>3) and antiplatelet therapy, 
alongside vasodilators. Improvement in ischaemic 
lesions (after increasing target INR and IV vasodilators). 
23M (smoker) with 3-month history of pain and 
progressive cyanosis of left 4th toe (52) 
aPLs (not specified)* Anticoagulation (INR2.5-3) with resolution and no 
recurrence at 6-months of follow-up 
50F with 2-week history of discolouration and pain of left 
digit/hand (53) 
 
aCL IgM (high titre-73 MPL)^  
anti-β2GPI IgG (high titre-63 
GPL)^ 
Anticoagulation (INR2-3), antiplatelet therapy and 
hydroxychloroquine. Switch from anti-TNF to anti-IL-
12/23. Resolution and no recurrence at 57-months of 




Prolonged dRVVT (ratio 1.55) follow-up (39-months without anticoagulation) 
With digital ischaemic necrosis 
77M with 2-week history of digital ischaemia, 
complicated by necrosis, and previous DVT and CVA (54) 
ACL IgG (positive-49 HU)* 
LAC*ⱡ 
Resolution after anticoagulation with no recurrence at 
6-months 
64F with digital necrosis of multiple fingers and toes, and 
previous miscarriages (3 of unknown gestation) and 
cerebellar infarcts on CT (2) (55) 
Anti-PT* Initial antiplatelet therapy with relapse of digital 
necrosis. Aanticoagulation (INR 3-4) initiated with 
resolution and no recurrence. 
73F with digital ischaemia/gangrene (hands and feet) 
(56) 
 
LAC Anticoagulation with vasodilators. Gangrene resolved 
(some onrgoing autoamputation) with no recurrence at 
6-months  
70M with bilateral digital necrosis with a background 2-
month history of RP (47) 
anti-β2GPI IgG (high titre-93.80 
and 205 GPL ,12 weeks apart) 
Anticoagulation with improvement, and no recurrence 
at 9-months  
 
*Repeat testing at 12-weeks not described 
^Repeat testing occurred, but no further details provided 
ⱡCase report prior to updated Sydney classification criteria (2006)  
aCL, anti-cardiolipin antibody; aPLs, anti-phospholipid antibodies; anti-β2GPI, anti-beta-2 glycoprotein 1 antibody; anti-PT, anti-
prothrombin antibody; CT, computed tomography; CVA, cerebrovascular accident; dRVVT, dilute Russell viper venom time; DVT, deep 
vein thrombosis;  F, female; GPL, IgG phospholipid units HU, Hammersmith units; INR, international normalised ratio; IgG, 
immunoglobulin G, IgM, immunoglobulin M, IV, intravenous; LAC, lupus anticoagulant; M, male; MPL, IgM phospholipid units NR, 
not reported; PE, pulmonary emboli; RP, Raynaud’s phenomenon 
 
